Martingale Asset Management L P Buys 1,000 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Martingale Asset Management L P increased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,265 shares of the company’s stock after buying an additional 1,000 shares during the quarter. Martingale Asset Management L P owned approximately 0.08% of Amphastar Pharmaceuticals worth $1,954,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC lifted its stake in Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after acquiring an additional 273 shares during the last quarter. Innealta Capital LLC bought a new position in Amphastar Pharmaceuticals during the second quarter worth about $55,000. Blue Trust Inc. increased its position in Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after buying an additional 309 shares during the last quarter. Asset Management One Co. Ltd. bought a new stake in Amphastar Pharmaceuticals in the third quarter valued at approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after buying an additional 301 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the sale, the director now directly owns 75,409 shares of the company’s stock, valued at approximately $3,504,256.23. This represents a 3.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Rong Zhou sold 6,893 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $48.88, for a total value of $336,929.84. Following the completion of the transaction, the executive vice president now owns 118,388 shares in the company, valued at $5,786,805.44. The trade was a 5.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,533 shares of company stock valued at $1,378,252 over the last 90 days. 27.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AMPH. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 target price on the stock. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $60.33.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ:AMPH opened at $45.19 on Friday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The company’s 50 day moving average price is $47.83 and its two-hundred day moving average price is $44.55. The firm has a market cap of $2.17 billion, a PE ratio of 15.06, a PEG ratio of 0.90 and a beta of 0.82.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.